EGFR and breast cancer: Considering the role of EGFR and its downstream pathway in regulation of epithelial-mesenchymal transition, migration, and tumor invasion in breast cancer and the availability of drugs that target this pathway [19], alterations in the expression of SOCS5 in breast cancer might be involved in the response of patients to such targeted therapies.